Keywords: Cypress Biosciece, Ramius, Royalty Pharma, savella, M&A, Accepts revized offer

Cypress Bioscience finally succumbs to Ramius advances, but at $6.50/share in cash

Article | 16 December 2010

Print This

In the now nearly five month saga, Cypress Biosciences (Nasdaq CYPB) has done an about turn and accepted the takeover ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in